Teva also agrees to withdraw Irish equivalent to U.S. patents from litigation in Ireland HERTFORDSHIRE, Englandand PITTSBURGH, Dec. 11, 2017/PRNewswire / -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that Teva has dismissed its pending district court litigation against Mylan regarding Mylan`s Glatiramer Acetate Injection 40 mg/mL, the first generic version of Copaxone 40 mg/mL. The litigation involved two non-Orange Book listed patents, U.S. Patent Nos. 9,155,775 and 9,763,993, relating to the final sterile filtration step in the manufacturing process for glatiramer acetate products. Teva dropped litigation on these patents after the U.S. District Court for the District of Delawareissued...
|
